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INTRODUCTION:  
Chemical Nomenclature of Telmisartan (TEL) 4'-
[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-
1'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid 
(144701-48-4 ) (Fig. 1). It is an angiotensin II 
receptor antagonist of PPARγ, influence the 
expression of PPARγ target genes involved in the 
regulation of carbohydrate and lipid metabolism and 
reduces glucose, insulin and triglyceride levels and 
widely used in hypertensive[1] and non-competitive 
inhibition [2]. Since TEL has high pharmacologically 
active with respect to other antihypertensive 
molecule, it is necessary to identify, characterize and 
quantify it as an active pharmaceutical ingredient. 
Several high-performance liquid chromatography 
(HPLC) and some reverse phase HPLC methods have 
been reported for a single drug in bulk, 
pharmaceutical formulation and in combination.[3-7] 
Ultra performance liquid chromatography (UPLC) 
and liquid chromatography-mass spectrometry 
method have also been reported for the quantitative 
and qualitative analysis for TEL.[8-9] 
 
Fig-1 Telmisartan (TEL) 
Nowadays NMR spectroscopy has found new tool for 
quantitative for the determination of pharmaceutical 
potent biologically active molecules in bulk drug and 
its tablet formulation than the other analytical 
techniques. Jadeja Y. et al gave Herein, qNMR 
method was developed for an anti-hypertensive drug, 
telmisartan in bulk drug and its tablet formulation. 
The developed method by 1H NMR spectroscopy is 
comparatively easy and more precise with respect to 
the other analytical tools. [10] 
Telmisartan was known as  angiotensin receptor 
blocker and PPAR-γ agonist with potential anti-
inflammatory and metabolic benefits. Catherine N. 
Le and it’s co-workers  assessed how telmisartan's 
produce effect on urine eicosanoids among HIV+ 
adults with central adiposity on suppressive 
antiretroviral therapy enrolled in a prospective 
clinical trial.[11] 
Jordan E. Lake  et al made a pilot study and they 
demonstrated that 12 weeks of standard dose 
telmisartan therapy was related with improved EPC 
count and EPC commitment to endothelial lineage in 
grown-up HIV-1-infected individuals with 
conventional CVD hazard. This study is the first to 
assess telmisartan’s effects on EPCs in HIV 
infection, and suggests that vascular reparative ability 
can be modulated in unremitting, treated HIV 
infection.[12] 
Telmisartan also restrict NFAT nuclear translocation 
and ANP/BNP expression. NFAT is an important 
nuclear transcriptional factor to take part in cardiac 
hypertrophy [13] Thus, Pu WT et al were 
investigated whether telmisartan inhibited NFAT 
nuclear translocation. There are five subtypes of 
NFAT in cardiomyocytes, however, it is thought that 
NFATc3 and NFATc4 are the majority expressed in 
cardiomyocytes, and therefore NFATc3 and NFATc4 
may be the two most important subtypes [14]. 
The study done by Xiurong Li et al demonstrated that 
telmisartan suppressed cardiomyocyte hypertrophy in 
vivo and in vitro, effectively by suppressing 
cardiomyocyte ANP/BNP expression and apoptosis, 
which may be lie on the inhibition of NFAT nuclear 
translocation. These results may provide a unique 
insight into the mechanism of telmisartan‑ induced 
cardiomyocyte hypertrophy inhibition [15] 
It was also seen that the Telmisartan suppresses the 
development of endometriotic lesions. but, the drug 
furthermore up-regulates the expression of 
cyclooxygenase (COX)-2, which has been suggested 
to promote the progression of endometriosis. 
Accordingly, we herein analyzed whether a 
combination therapy with telmisartan and a COX-2 
inhibitor may be more effective in the treatment of 
endometriotic lesions than application of telmisartan 
alone. Telmisartan-treated lesions exhibited a 
extensively minimized lesion volume when compared 
to vehicle-treated controls and parecoxib-treated 
lesions. This inhibitory effect of telmisartan was even 
more pronounced in combination with parecoxib. The 
combination therapy resulted in a reduced 
microvessel density as well as lower numbers of 
proliferating Ki67-positive cells and higher numbers 
of apoptotic cleaved caspase-3-positive stromal cells 
within the lesions. This was associated with a lower 
expression of COX-2, matrix metalloproteinase 
(MMP)-9 and p-AKT/AKT when compared to 
controls. The application of the two drugs further 
inhibited the in growth of nerve fibers into the 
lesions[16] 
J. Zhang and co-workers utilized computational 
techniques for the sake of details on the binding 
interactions and conformational stability. In past 
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angiotensin II receptor blockers not only antagonize 
angiotensin II type 1 receptor (AT1R), but also exert 
stimulation in peroxisome proliferator-activated 
receptor γ (PPARγ) partial start, among which 
telmisartan showed the finest. Telmisartan has been 
tested as a bifunctional ligand with antihypertensive 
and hypoglycemic activity. Aiming at more potent 
leads with selective AT1R antagonism and PPARγ 
partial agonism, the three parts of telmisartan 
including the distal benzimidazole ring, the biphenyl 
moiety, and the carboxylic acid group experienced 
modification. Standard precision docking analysis 
and absorption, distribution, metabolism, excretion, 
and toxicity prediction received 10 molecules with 
higher Glide scores, similar interactions, and 
improved pharmacokinetic profiles compared to 
telmisartan as shown in fig.2 [17] 
 
Anjali Sharma et al were studied S-TEL-PEG-CNPs 
which shown promising consequences in preliminary 
investigations for the treatment of cervical cancer 
through non-invasive intravaginal route. S-TEL-
PEG-CNPs have shown promising consequences in 
preliminary investigations for the treatment of 
cervical cancer through non-invasive intravaginal 
route.[18] 
M. Kaur et al investigated soluble telmisartan [19] 
was encapsulated in poly (ethylene glycol) grafted 
chitosan nanoparticles (S-TEL-PEGCNPs) by ionic 
gelation method [20]. In addition, telmisartan loaded 
poly (ethylene glycol) conjugated chitosan 
nanoparticles (TEL-PEGCNPs) and blank chitosan 
nanoparticles (PEG-CNPs and CNPs) were also 
formulated for comparative studies. Initially, acetic 
acid functionalized poly (ethylene glycol) (mPEG-
CH2COOH) was conjugated to primary amine group 
of chitosan by activating the carboxylic acid terminus 
[21]. The conjugation reaction was confirmed by FT-
IR spectroscopy. 
 
 
 
 
Fig-2: The interactions of telmisartan AT1R (left) and PPARγ (right) ligand-binding pockets 
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Pinaki Sengupta et al developed and validated a high 
throughput LC-MS/MS method for simultaneous 
quantitation of pioglitazone and telmisartan in rat 
plasma. This developed method is more sensitive and 
able to quantitate the analytes in relatively shorter 
period of time compared to the previously reported 
methods for their individual quantification. 
Moreover, till date, there is no bioanalytical method 
available to simultaneously quantitate pioglitazone 
and telmisartan in a single run. The method has been 
validated according to the USFDA guidelines for 
bioanalytical method validation.[22] 
Telmisartan (TLM), an angiotensin type 1 receptor 
blocker (ARB) antihypertensive has been shown to 
have significant PPAR-γ receptor activation capacity 
[23-25]. Amongst all the tested antihypertensive 
agents, the binding affinity for TLM to PPAR-γ has 
been reported to be the highest. Due to this 3 
uniqueness, TLM shows beneficial antidiabetic 
effects in diabetic patient independent of their 
antihypertensive effects [26-27]. 
Telmisartan although reduces glucose levels and 
improves beta cell mass but the effect is statistically 
non-significant as compared to pioglitazone. In 
hypertensive type 2 diabetics a combination of these 
two drugs may help in reducing the dose of 
pioglitazone and consequently the cardiovascular 
adverse effects of pioglitazone[28]. 
 
Suzuki reaction catalyzed by either a homogeneous 
palladium source or graphene-supported palladium 
nanoparticles. The cross-coupling reaction was 
facilitated by the regio-controlled preparation of the 
2-bromo-1-methylbenzimidazole precursor. This 
convergent approach provides telmisartan shown in 
scheme 1 [29] 
N
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Scheme-1 
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K. Reddy et al gave dibenzimidazole derivative of 
Telmisartan, shows antihypertensive drug, essentially 
used to control blood pressure shown in scheme 2  
[30]. 
 
C. Chunxia and Co-workers has been described 
method for the synthesis of the benzimidazole ring 
system through a carbon-nitrogen cross-coupling 
reaction. In the presence of K2CO3 in water at 100 
°C, the intramolecular ring formation of N-(2-
iodoaryl) benzamidine to gets benzimidazole 
derivatives. The procedure occurs exclusively in 
water and doesn’t require the use of any additional 
reagent/catalyst, rendering the methodology highly 
valuable from both environmental and economical 
points of view shown in fig 3. [31] 
 
 
  
 
Scheme 2 
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T V Maruthikumar et al gave a synthesis of the 
angiotensin II receptor antagonist telmisartan is 
described. It involves Suzuki coupling of 4-
formylphenylboronic acid with 2-(2-bromophenyl)-
4,4-dimethyl-2- oxazoline followed by construction 
of benzimidazole moiety regioselectively though a 
reductive amination-condensation sequence, 
replacing the earlier alkylation of the preformed 
benzimidazole route. This methodology overcomes 
many drawbacks of the reported synthesis shown in 
scheme 3.[32] 
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A. S. Kumar et al studied a highly efficient, 
convergent approach to the synthesis of the 
angiotensin II receptor antagonist telmisartan (1) is 
described. Involving a Suzuki coupling of 4-
(hydroxymethyl)phenylboronic acid with 2-(2- 
bromophenyl)-4,4-dimethyl-2-oxazoline as the key 
step. The bisbenzimidazole moiety is constructed 
alternatively via an N-alkylation-condensation 
sequence, this convergent synthesis with the 
sequence consisting of six steps shown in scheme 
4[33] . 
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The reduction of nitro compound 5 to obtain amine 6, 
the resulting reaction mass was filtered to remove Pd-
C catalyst and the filtrate was concentrated to a thick 
syrup which was directly react with aqueous sodium 
hydroxide to get benzimidazole intermediate 8 after 
adjusting pH between 4.5 and 5.0 with concd HCl in 
a one step Fig 1 .  
 
Reddy, Kikkuru S  and coworkers studied further 
intermediate 8 was then condensed with N-methyl-
benzene-1,2-found in 10 were desmethyl 
dibenzimidazole (18) which may be due to the 
presence of traces of benzene-1,2-diamine in 9, 7-
methyl-2-propyl-3H-benzoimidazole-5-carboxylic 
acid (2-methylaminophenyl)amide (19), and 3-
amino-4-butyrylamino- 5-methyl-N-(2-
methylaminophenyl)benzamide (20) [34]. 
 
 
 
 
 
 
Scheme-5 
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Scheme-6 
In another findings by Sanjeev Kumar, shows the 
synthesis of the angiotensin II receptor antagonist 
Telmisartan (1) is presented involving The reductive 
amination of the biaryl aldehyde 12 with amine 13  
was carried out in the presence of p-toluenesulfonic 
acid in toluene and followed by hydrogenation in 
methyl alcohol. The resulting amine 14 was not 
isolated but cyclized in situ to the n-propyl 
benzimidazole 15 in refluxing glacial acetic acid. 
Finally, cleavage of the oxazoline moiety in 15 by 
acid afforded Telmisartan (1) shown in scheme 7 [35] 
 
Scheme-7 
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Scheme-8 
Goossen, Lukas J et al examined an efficient 
synthesis of the angiotensin II receptor antagonist 
telmisartan is described  decarboxylative cross-
coupling of isopropyl phthalate (1) with 2-(4-
chlorophenyl)-1,3-dioxolane (2c) as the key step. The 
benzimidazole moiety is constructed regioselectively 
via a reductive amination−condensation sequence, 
replacing the previously published route via 
alkylation of the preformed benzimidazole shown in 
scheme 8[36].  
 
And some heterocyclic drugs synthesis via several 
name reactions [37-41]. 
 
CONCLUSION:  
The current review article emphasizes broadly over 
several scalable approaches carried out toward the 
syntheses of Telmisartan drug which are 
commercially available in the market and this should 
serve the purpose for those who aspire to come out 
with cost effective, ecofriendly and robust alternative 
approaches towards synthesis of existing Telmisartan  
drugs. 
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